The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Gland Pharma's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Gland Pharma's Dividend Payout Ratio or its related term are showing as below:
NSE:GLAND'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.28 Med: 0.38 Max: 0.47
Current: 0.28
During the past 9 years, the highest Dividend Payout Ratio of Gland Pharma was 0.47. The lowest was 0.28. And the median was 0.38.
NSE:GLAND's Dividend Payout Ratio is ranked better than 64.41% of 444
companies
in the Drug Manufacturers industry
Industry Median: 0.375
vs NSE:GLAND: 0.28
During the past 12 months, Gland Pharma's average Dividends Per Share Growth Rate was -10.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Gland Pharma (NSE:GLAND) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gland Pharma Dividend Payout Ratio Related Terms
Gland Pharma Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAND vs ZTS, UTHR: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Gland Pharma's Dividend Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gland Pharma and its competitors. Over the past decade, Gland Pharma's Dividend Payout Ratio has ranged from 0.28 to 0.47. According to the industry distribution chart, Gland Pharma ranks #158 out of 444 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Gland Pharma's Dividend Payout Ratio too high?
Gland Pharma's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.47. Based on the distribution chart, Gland Pharma ranks #158 out of 444 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #158 out of 444 companies for Dividend Payout Ratio. This puts Gland Pharma in the upper half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, Gland Pharma's own Dividend Payout Ratio has ranged from 0.28 to 0.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
Dividend Payout Ratio: 0.00
GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
